

Curriculum Vitae

Personal information Denis Lacombe

Work experience

1. Employer: EORTC
 - Start date: 091993
 - End date: 091996
 - Position: Medical Supervisor
 - Activities:
 - Country: Belgium
2. Employer: EORTC
 - Start date: 101996
 - End date: 012007
 - Position: Head of the Investigational Agent Unit
 - Activities:
 - Country: Belgium
3. Employer: EORTC
 - Start date: 031996
 - End date: 112007
 - Position: Head of EORTC Intergroup Office
 - Activities:
 - Country: Belgium
4. Employer: EORTC
 - Start date: 031997
 - End date: 112007
 - Position: Head of Pharmacovigilance Unit
 - Activities:
 - Country: Belgium
5. Employer: EORTC
 - Start date: 031997
 - End date: 112007
 - Position: Head of Regulatory Affairs Unit
 - Activities:
 - Country: Belgium
6. Employer: EORTC
 - Start date: 011998
 - End date: 112007
 - Position: Assistant Director Medical Affairs/New Drug Development Team
 - Activities:
 - Country: Belgium
7. Employer: EORTC
 - Start date: 011998
 - End date: 122010
 - Position: Chairman EORTC Institutional Review Board
 - Activities:
 - Country: Belgium
8. Employer: EORTC
 - Start date: 011999
 - End date: 122010
 - Position: Clinical Research Physician Brain Tumor
 - Activities:
 - Country: Belgium
9. Employer: EORTC
 - Start date: 012003
 - End date: 122009
 - Position: Head and Neck Tumor Group
 - Activities:
 - Country: Belgium
10. Employer: EORTC
 - Start date: 112007
 - End date: 112010
 - Position: Scientific Director
 - Activities:
 - Country: Belgium
11. Employer: EORTC
 - Start date: 012009
 - End date: 122011
 - Position: Clinical Research Physician Lung Group
 - Activities:
 - Country: Belgium
12. Employer: EORTC
 - Start date: 012005
 - End date: 042015
 - Position: Coordinator Fellowship Program
 - Activities:
 - Country: Belgium
13. Employer: EORTC

- Start date: 112010
 - End date: 042015
 - Position: Director, EORTC Headquarters
 - Activities:
 - Country: Belgium
14. Employer: EORTC
- Start date: 042015
 - End date:
 - Position: Director General/Chief Executive Officer (CEO)
 - Activities:
 - Country: Belgium

Education and training

1. Subject: Toulon
 - Start date:
 - End date: 1980
 - Qualification: High School Graduation _ French Baccalaureate
 - Organisation:
 - Country: France
2. Subject: Marseilles
 - Start date:
 - End date: 1981
 - Qualification: Medical School
 - Organisation:
 - Country: France
3. Subject: Marseilles
 - Start date: 1983
 - End date: 1985
 - Qualification: Pharmacology master composed of three certificates
 - Organisation: Pharmacology master composed of three certificates: _ General pharmacology _ General physiology _ Basis of radio_isotopes use in medicine and radiobiology
 - Country: France
4. Subject: Marseilles
 - Start date:
 - End date: 1988
 - Qualification: Medical Thesis
 - Organisation:
 - Country: France
5. Subject: Post_doctoral fellowship Roswell Park Center Institute
 - Start date: 1989
 - End date: 1991
 - Qualification: Fundamental and Clinical Pharmacokinetics Master
 - Organisation:
 - Country: United States

Additional information

Publications

1. LACOMBE D., MEUNIER F. Patients' rights: The specificity and requirements of high_quality clinical research and its impact on patient_doctor communication. *Revue de Droit de la Santé (Ministère Belge)* 1997_1998; 365: 405_411. 2. DE BOUYALSKI I., LACOMBE D. The Development of the Guidelines and Recommendations for European Ethics Committees by the European Forum for Good Clinical Practice. *International Journal of Pharmaceutical Medicine* 1997; 11: 125_127. 3. LACOMBE D. Ethical Issues in Cancer Clinical Trials: A European Perspective. *European Journal of Cancer* 1997; 33(2): 184_185. 4. LACOMBE D. Insuring International Clinical Trials. *An Academic Viewpoint. Applied Clinical Trials* 1998; 7(3): 24_29. 5. LACOMBE D., THERASSE P., MEUNIER F. Obstacles for Independent Transnational Clinical Trials in Europe. *International Journal of Pharmaceutical Medicine* 1998; 12(3): 133_136. 6. LACOMBE D. How will changes in GCP regulations affect non_profit organisations conducting academic clinical research? *Good Clinical Practice Journal* 1999; 6(1): 38_40. 7. VINHOLES J., COLEMAN R., LACOMBE D., ROSE C., TUBIANA_HULIN M., BASTIT P., WILDIERS J., MICHEL J., LEONARD R., NORTIER J., MIGNOLET F., and FORD J. Assessment of bone response to systemic therapy in an EORTC trial: preliminary experience with the use of collagen cross_link excretion. *British Journal of Cancer* 1999; 80(1/2): 221_228. 8. DUBOIS N., LACOMBE D. SAE Report Handling in a Multinational Academic Research Environment. *Applied Clinical Trials* 2000; 38_44. 9. PICCART MJ., GREEN JA., JIMENEZ LACAVE A., REED N., VERGOTE I., BENEDETTI PANICI P., BONETTI A., KRISTELLER TOME V., MENDIOLA FERNANDEZ C., CURRAN D., VAN GLABBEKE M., LACOMBE D., PINEL M.C., and PECORELLI S. Oxaliplatin or Paclitaxel in patients with platinum pretreated advanced ovarian cancer: A randomized phase II study of the European Organization for Research and Treatment of Cancer Gynecology Group. *Journal of Clinical Oncology* 2000; 18(6): 1193_1202. 10. MARINUS A., LACOMBE D. Cancer Clinical Trials in Europe: issues and challenges, the academic point of view of the EORTC. *Good Clinical Practice Journal* 2000; 7(3): 15_18. 11. BRANDES AA., LACOMBE D., VECHT C. Future trends in the treatment of brain tumours. *European Journal of Cancer* 2001; 37(18): 2297_2301. 12. CAPONIGRO F., DITTRICH C., SORENSEN J.B., SCHELLEN JHM., DUFFAUD F., PAZ ARES L., LACOMBE D., DE BALINCOURT C., FUMOLEAU P. Phase II study of XR 5000, an inhibitor of topoisomerases I and II, in advanced colorectal cancer. *European Journal of Cancer* 2002; 38(1): 70_74. 13. VECHT C., VAN DEN BENT MJ., LACOMBE D. EORTC Brain Tumor Group: Achievements and perspectives. *European Journal of Cancer* 2002; 38(Suppl.4): S35_S38. 14. LACOMBE D., FUMOLEAU P., ZWIERZINA H., TWELVES C., HAKANSSON L., JAYSON G., LEHMANN F., VERWEIJ J. The EORTC and drug development. *European Journal of Cancer* 2002; 38(Suppl. 4): S19_S23. 15. TWELVES C., CAMPONE M., COUDERT B., VAN DEN BENT M., DE JONGE M., DITTRICH C., RAMPLING R., SORIO R., LACOMBE D., DE BALINCOURT C., FUMOLEAU P. Phase II study of XR5000 (DACA) administered as a 120_h infusion in patients with recurrent glioblastoma multiforme. *Annals of Oncology* 2002; 13(5): 777_780. 16. BAEYENS AJ., LACOMBE D. Regulatory issues for clinical trials at EORTC: The way forward. *European Journal of Cancer* 2002; 38 (Suppl.4): S142_S146. 17. DEBBAUDT A., ROCHE L., LACOMBE D., BAEYENS AJ. EORTC's Regulatory Affairs Unit: Facilitating European Cancer Research. *Applied Clinical Trials* 2002; 61_66. 18. RAYMOND E., CAMPONE M., STUPP R., MENTEN J., CHOLLET P., LESIMPLE T., FETY DEPORTE R., LACOMBE D., PAOLETTI X., FUMOLEAU P. Multicentre phase II and pharmacokinetic study of RFS2000 (9_nitro_camptothecin) administered orally 5 days a week in patients with glioblastoma multiforme. *European Journal of Cancer* 2002; 38(10): 1348_1350. 19. LACOMBE D., REA LA., MEUNIER F. La nouvelle législation de l'UE pourrait entraver la recherche clinique et académique sur le cancer. *EJHP* 2003; 3: 14_18. 20. LACOMBE D., BRANDES AA., VAN DEN BENT M. The European Organisation for Research and Treatment of Cancer Strategy for New Drug Development in Brain Tumors. *Seminars in Oncology* 2003; 30, No 6 (Suppl.19): 77_80. 21. LACOMBE D., REA LA., MEUNIER F. New EU legislation may hinder academic clinical cancer research. *EJHP* 2003; 3: 14_18. 22. MEUNIER F., LACOMBE D. European Organisation for Research and Treatment of Cancer's point of view. *Lancet* 2003; 362 (9384): 663. 23. LEHMANN F., LACOMBE D., THERASSE P., EGGERMONT AMM. Integration of Translational Research in the European Organization for Research and Treatment of Cancer Research (EORTC) Clinical Trial Cooperative Group Mechanisms. *Journal of Translational Medicine* 2003; 1(1): 2_24. BRIASOULIS E., PAVLIDIS N., TERRET C., BAUER J., FIEDLER W., SCHÖFFSKI P., RAOUL JL., HESS D., SELVAIS R., LACOMBE D., BACHMANN P., FUMOLEAU P. Glufosfamide administered using a 1_hour infusion given as first_line treatment for advanced pancreatic cancer. A phase II trial of the EORTC_New Drug Development Group. *European Journal of*

Cancer 2003; 39(16): 2334_2340. 25. VAN DEN BENT M.J., GRISOLD W., FRAPPAZ D., STUPP R., DESIR JP., LESIMPLE T., DITTRICH C., DE JONGE MJA., BRANDES A., FRENAY M., CARPENTIER AF., CHOLLET P., OLIVEIRA J., BARON B., LACOMBE D., SCHUESSLER M., FUMOLEAU P. European Organization for Research and Treatment of Cancer (EORTC) open label phase II study on glufosfamide administered as a 60_ minute infusion every 3 weeks in recurrent glioblastoma multiforme. *Annals of Oncology* 2003; 14(12): 1732_1734. 26. DITTRICH C., DIERAS V., KERBRAT P., PUNT C., SORIO R., CAPONIGRO F., PAOLETTI X., DE BALINCOURT C., LACOMBE D., FUMOLEAU P. Phase II study of XR5000 (DACA), an inhibitor of topoisomerase I and II, administered as a 120_h infusion in patients with advanced ovarian cancer. *Investigational New Drugs* 2003; 21(3): 347_352. 27. LACOMBE D., PASSIOUKOV A., HILL B. The need for innovative design in modern cancer clinical trials. *Oncologie* 2003; 5: 305_310. 28. LACOMBE D., CROTT R., MEUNIER F. EORTC Research and Development: Achievements and Future Perspectives. *Advances in Experimental Medicine and Biology* 2003; 532: 269_276. 29. LACOMBE D., CROTT R., MEUNIER F. New Anticancer Agents: An Embattled Future. *Hospital Decisions – Spring* 2003; 149_151. 30. MEUNIER F., LACOMBE D. The EORTC and its Pan_European New Drug Development Program for Cancer. *Business Briefing: Future Drug Discovery* 2003; 14_15. 31. LACOMBE D., BUTLER SMITH A., THERASSE P., FUMOLEAU P., BURTLES S., CALVERT H., MARSONI S., SESSA C., VERWEIJ J. Cancer Drug Development in Europe: A Selection of New Agents under Development at the European Drug Development Network. *Cancer Investigation* 2003; 21(1): 137_147. 32. DITTRICH C., COUDERT B., PAZ_ARES L., CAPONIGRO F., SALZBERG M., GAMUCCI T., PAOLETTI X., HERMANS C., LACOMBE D., FUMOLEAU P. Phase II study of XR 5000 (DACA), an inhibitor of topoisomerase I and II, administered as a 120_h infusion in patients with non_small cell lung cancer. *European Journal of Cancer* 2003; 39(3): 330_334. 33. DUFFAUD F., BORNER M., CHOLLET P., VERMORKEN JB., BLOCH J., DEGARDIN M., ROLLAND F., DITTRICH C., BARON B., LACOMBE D., FUMOLEAU P. Phase II study of OSI_211 (liposomal lurtotecan) in patients with metastatic or loco_regional recurrent squamous cell carcinoma of the head and neck. An EORTC New Drug Development Group Study. *European Journal of Cancer* 2004; 40(18): 2748_2752. 34. SCHÖFFSKI P., RIGGERT S., FUMOLEAU P., CAMPONE M., BOLTE O., MARREAUD S., LACOMBE D., BARON B., HEROLD M., ZWIERZINA H., WILHELM_OGUNBIYI K., LENTZEN H., TWELVES C. Phase I trial of intravenous aviscumine (rViscumin) in patients with solid tumors: a study of the European Organization for Research and Treatment of Cancer New Drug Development Group. *Annals of Oncology* 2004; 15(12): 1816_1824. 35. LACOMBE D., PASSIOUKOV A., MEUNIER F. De la découverte du radium aux thérapies ciblées. Une publication de l'European Organization for Research and Treatment of Cancer (EORTC) parrainée par le Leem «Les entreprises du médicament», dossier cancer 2004. 36. DE BALINCOURT C., MARREAUD S., PLACCHI M., VANDAELE B., LACOMBE D. Project Management Platform in an academic environment: The EORTC's promising experience. *Applied Clinical Trials* 2004; 13(8): 28_32. 37. VAN DEN BENT MJ., STUPP R., BRANDES AA., LACOMBE D. Current and Future Trials of the EORTC Brain Tumor Group. *Onkologie* 2004; 27(3): 246_250. 38. PUNT CJA., DE JONGE MJA., MONFARDINI S., DAUGAARD G., FIEDLER W., BARON B., LACOMBE D., FUMOLEAU P. RFS2000 (9_nitrocarnptothecin) in advanced small cell lung cancer, a phase II study of the EORTC New Drug Development Group. *European Journal of Cancer* 2004; 40(9): 1332_1334. 39. DE JONGE MJA., DROZ JP., PAZ_ARES L., VAN OOSTEROM AT., DE WIT R., CHOLLET P., BARON B., LACOMBE D., METTINGER K., and FUMOLEAU P. Phase II study on 9_nitrocarnptothecin (RFS 2000) in patients with advanced or metastatic urothelial tract tumors. *Investigational New Drugs* 2004; 22(3): 329_333. 40. GIACCONE G., SMIT EF., DE JONGE M., DANSIN E., BRIASOULIS E., ARDIZZONI A., DOUILLARD JY., SPAETH D., LACOMBE D., BARON B., BACHMANN P., FUMOLEAU P. Glufosfamide administered by 1_hour infusion as a second_line treatment for advanced non_small cell lung cancer: a phase II trial of the EORTC_New Drug Development Group. *European Journal of Cancer* 2004; 40(5): 667_672. 41. TWELVES C., BIBBY M., LACOMBE D., BURTLES S. Drug Development in Europe: The Academic Perspective. *Cancer Drug Discovery and Development; Anticancer Drug Development Guide: Preclinical Screening, Clinical Trials and Approval*, 2nd Edition 2004. Humana Press, Totowa, NJ, 2004, 381_399. 42. DIERAS V., BONNETERRE J., LAURENCE V., DEGARDIN M., PIERGA JY., BONNETERRE ME., MARREAUD S., LACOMBE D., FUMOLEAU P. Phase I combining a P_glycoprotein inhibitor, MS209, in combination with docetaxel in patients with advanced malignancies. *Clinical Cancer Research* 2005; 11(17): 6256_6260. 43. THEODORE C., GEOFFROIS L., VERMORKEN JB., CAPONIGRO F., FIEDLER W., CHOLLET P., RAVAUD A., PETERS GJ., DE BALINCOURT C., LACOMBE D., FUMOLEAU P. Multicentre EORTC study 16997: Feasibility and phase II trial of farnesyl transferase inhibitor & gemcitabine combination in salvage treatment of advanced urothelial cancers. *European Journal of Cancer* 2005; 41(8): 1150_1157. 44. STUPP R., MASON WP., VAN DEN BENT MJ., WELLER M., FISHER B., TAPHOORN MJB., BELANGER K., BRANDES AA., MAROSI C., BOGDHANN U., CURSCHMANN J., JANZER RC., LUDWIN SK., GORLIA T., ALLGEIER A., LACOMBE D., CAIRNCROSS JG., ELIZABETH EISENHAUER E., MIRIMANOFF RO., for the European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups and the National Cancer Institute of Canada Clinical Trials Group. Radiotherapy plus Concomitant and Adjuvant Temozolamide for Glioblastoma. *The New England Journal of Medicine* 2005; 352(10): 987_996. 45. PAOLETTI X., BARON B., SCHÖFFSKI P., FUMOLEAU P., LACOMBE D., MARREAUD S., SYLVESTER R. Using the continual reassessment method: Lessons Learned from an EORTC phase I dose finding study. *European Journal of Cancer* 2006; 42(10): 1362_1368. 46. DE JONGE MJ., DUMEZ H., VERWEIJ J., YARKONI S., SNYDER D., LACOMBE D., MARREAUD S., YAMAGUCHI T., PUNT CJ., VAN OOSTEROM A., on behalf of the EORTC New Drug Development Group (NDDG). Phase I and pharmacokinetic study of halofuginone, an oral quinazolinone derivative in patients with advanced solid tumours. *European Journal of Cancer* 2006; 42(12): 1768_1774. 47. MIRIMANOFF RO., GORLIA T., MASON W., VAN DEN BENT MJ., KORTMANN RD., FISHER B., RENI M., BRANDES AA., CURSCHMANN J., VILLA S., CAIRNCROSS G., ALLGEIER A., LACOMBE D., STUPP R. Radiotherapy and temozolamide for newly diagnosed glioblastoma: recursive partitioning analysis of the EORTC 26981/22981_NCIC CE3 phase III randomized trial. *Journal of Clinical Oncology* 2006; 24(16): 2563_2569. 48. VAN DEN BENT MJ., CARPENTIER AF., BRANDES AA., SANSON M., TAPHOORN MJ., BERNSEN HJ., FRENAY M., TIJSSEN CC., GRISOLD W., SIPOS L., HAAXMA REICHE H., KROS JM., VAN KOUWENHOVEN MC., VECHT CJ., ALLGEIER A., LACOMBE D., GORLIA T. Adjuvant Procarbazine, Lomustine, and Vincristine Improves Progression-Free Survival but Not Overall Survival in Newly Diagnosed Anaplastic Oligodendrogliomas and Oligoastrocytomas: A Randomized European Organisation for Research and Treatment of Cancer Phase III Trial. *Journal of Clinical Oncology* 2006; 24(18): 2715_2722. 49. FIEDLER W., TCHEN N., BLOCH J., FARGEOT P., SORIO R., VERMORKEN J.B., COLLETTE L., LACOMBE D., TWELVES C. A study from the EORTC new drug development group: Open label phase II study of sabarubicin (MEN_10755) in patients with progressive hormone refractory prostate cancer. *European Journal of Cancer* 2006; 42(2): 200_204. 50. TAPHOORN MJ., VAN DEN BENT MJ., MAUER ME., COENS C., DELATTRE JY., BRANDES AA., SILLEVIS SMITT PA., BERNSEN HJ., FRENAY M., TIJSSEN CC., LACOMBE D., ALLGEIER A., BOTTOMLEY A. Health_related quality of life in patients treated for anaplastic oligodendroglioma with adjuvant chemotherapy: results of a European Organisation for Research and Treatment of Cancer randomized clinical trial. *Journal of Clinical Oncology* 2007; 25(36): 5723_5730. 51. MAUER M., TAPHOORN M., BOTTOMLEY A., COENS C., EFFICACE F., SANSON M., BRANDES AA., VAN DER RIJST C., BERNSEN H., FRENAY M., TIJSSEN CC., LACOMBE D., VAN DEN BENT MJ. Prognostic value of health_related quality_of_life data in predicting survival in patients with anaplastic oligodendrogliomas, from a phase III EORTC brain cancer group study. *Journal of Clinical Oncology* 2007; 25(36): 5731_5737. 52. YUN HJ., BOGAERTS J., AWADA A., LACOMBE D. Clinical trial design limitations in head and neck squamous cell carcinomas. *Current Opinion in Oncology* 2007; 19(3): 210_215. 53. VAN HERPEN CM., LOCATI LD., BUTER J., THOMAS J., BOGAERTS J., LACOMBE D., DE MULDER P., AWADA A., LICITRA L., BERNIER J., VERMORKEN JB. Phase II study on gemcitabine in recurrent and/or metastatic adenoid cystic carcinoma of the head and neck (EORTC 24982). *European Journal of Cancer* 2008; 44(17): 2542_2545. 54. RAYMOND E., BRANDES AA., DITTRICH C., FUMOLEAU P., COUDERT B., CLEMENT PM., FRENAY M., RAMPLING R., STUPP R., KROS JM., HEINRICH MC., GORLIA T., LACOMBE D., VAN DEN BENT MJ. Phase II study of imatinib in patients with recurrent gliomas of various histologies: a European Organisation for Research and Treatment of Cancer Brain Tumor Group Study. *Journal of Clinical Oncology* 2008; 26(28): 4659_4665. 55. BERGMANN L., AAMDAL S., MARREAUD S., LACOMBE D., HEROLD M., YAMAGUCHI T., WILHELM_OGUNBIYI K., LENTZEN H., ZWIERZINA H. Phase I trial of r_viscum (INN: aviscumine) given subcutaneously in patients with advanced cancer: a study of the European Organisation for Research and Treatment of Cancer (EORTC protocol number 13001). *European Journal of Cancer* 2008; 44(12): 1657_1662. 56. HILDEBRAND J., GORLIA T., KROS JM., AFRA D., FRENAY M., OMURO A., STUPP R., LACOMBE D., ALLGEIER A., VAN DEN BENT MJ.; on behalf of the EORTC Brain Tumour Group investigators. Adjuvant dibromodulcitol and BCNU chemotherapy in anaplastic astrocytoma: Results of a randomised European Organisation for Research and Treatment of Cancer phase III study (EORTC study 26882). *European Journal of Cancer* 2008; 44(9): 1210_1216. 57. GORLIA T., VAN DEN BENT MJ., HEGI ME., MIRIMANOFF RO., WELLER M., CAIRNCROSS JG., EISENHAUER E., BELANGER K., BRANDES AA., ALLGEIER A., LACOMBE D., STUPP R. Nomograms for predicting survival of patients

with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981_22981/CE.3. *Lancet Oncology* 2008; 9(1): 29_38. 58. EISENHAUER EA., THERASSE P., BOGAERTS J., SCHWARTZ LH., SARGENT D., FORD R., DANCEY J., ARBUCK S., GWYTHYER S., MOONEY M., RUBINSTEIN L., SHANKAR L., DODD L., KAPLAN R., LACOMBE D., VERWEIJ J. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). *European Journal of Cancer* 2009; 45(2): 228_247. 59. TRIMBLE EL., ABRAMS JS., MEYER RM., CALVO F., CAZAP E., DEYE J., EISENHAUER E., FITZGERALD T J., LACOMBE D., PARMAR M., SEIBEL N., SHANKER L., SWART AM., THERASSE P., VIKRAM B., VON FRENCKELL R., FRIEDLANDER M., FUJIWARA K., KAPLAN RS., and MEUNIER F. Improving cancer outcomes through international collaboration in academic cancer treatment trials. *Journal of Clinical Oncology* 2009; 27(30): 5109_5114. 60. GULYBAN A., FENTON P., FLAMENT J., LACOMBE D., MEUNIER F. L'assurance qualité en radiothérapie à l'EORTC _ 27 années d'expérience et perspectives. *Revue Multidisciplinaire d'Oncologie et Hématologie* 2009; 3(5): 180 _ 185. 61. KOUWENHOVEN MC., GORLIA T., KROS JM., IBDIAH A., BRANDES AA., BROMBERG JE., MOKHTARI K., VAN DUINEN SG., TEEPEN JL., WESSELING P., VANDENBOS F., GRISOLD W., SIPOS L., MIRIMANOFF R., VECHT CJ., ALLGEIER A., LACOMBE D., VAN DEN BENT MJ. Molecular analysis of anaplastic oligodendroglial tumors in a prospective randomized study: A report from EORTC study 26951. *Neuro. Oncology* 2009; 11(6): 737_746. 62. PALLIS AG., SERFASS L., DZIADZIUSZKO R., VAN MEERBEECK JP., FENNELL D., LACOMBE D., WELCH J., GRIDELLI C. Targeted therapies in the treatment of advanced/metastatic NSCLC. *European Journal of Cancer* 2009; 45 (14): 2473 _2487. 63. STERNBERG CN., DUMEZ H., VAN POPPEL H., SKONECZNA I., SELLA A., DAUGAARD G., GIL T., GRAHAM J., CARPENTIER P., CALABRO F., COLLETTE L., LACOMBE D. for the EORTC Genitourinary Tract Cancer Group. Docetaxel plus olabimersen sodium (Bcl_2 antisense oligonucleotide): an EORTC multicenter, randomized phase II study in patients with castration _resistant prostate cancer. *Annals of Oncology* 2009; 20(7): 1264_1269. 64. VAN DEN BENT MJ., DUBBINK HJ., SANSON M., VAN DER LEE HAARLOO CR., HEGI M., JEUKEN JW., IBDIAH A., BRANDES AA., TAPHOORN MJ., FRENAY M., LACOMBE D., GORLIA T., DINJENS WN., KROS JM. MGMT promoter methylation is prognostic but not predictive for outcome to adjuvant PCV chemotherapy in anaplastic oligodendroglial tumors: a report from EORTC Brain Tumor Group Study 26951. *Journal of Clinical Oncology* 2009; 27(35): 5881_5886. 65. LEFEBVRE JL., ROLLAND F., TESSELAAR M., BARDET E., LEEMANS CR., GEOFFROIS L., HUPPERETS P., BARZAN L., DE RAUCOURT D., CHEVALIER D., LICITRA L., LUNGHI F., STUPP R., LACOMBE D., BOGAERTS J., HORIOT JC., BERNIER J., VERMORKEN JB.; for the EORTC Head and Neck Cancer Group and the EORTC Radiation Oncology Group. Phase 3 randomized trial on larynx preservation comparing sequential vs alternating chemotherapy and radiotherapy. *Journal of the National Cancer Institute* 2009; 101(3): 142_152. 66. STUPP R., HEGI M., MASON WP., VAN DEN BENT MJ., TAPHOORN MJ., JANZER RC., LUDWIN SK., ALLGEIER A., FISHER B., BELANGER K., HAU P., BRANDES AA., GIJTENBEEK J., MAROSI C., VECHT CJ., MOKHTARI K., WESSELING P., VILLA S., EISENHAUER E., GORLIA T., WELLER M., LACOMBE D., CAIRNCROSS JG., MIRIMANOFF RO.; on behalf of the European Organisation for Research and Treatment of Cancer Brain Tumour and Radiation Oncology Groups; the National Cancer Institute of Canada Clinical Trials Group. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5_year analysis of the EORTC_NCIC trial. *Lancet Oncology* 2009; 10(5): 459_466. 67. VAN DEN BENT MJ., BRANDES AA., RAMPLING R., KOUWENHOVEN MC., KROS JM., CARPENTIER AF., CLEMENT PM., FRENAY M., CAMPONE M., BAURAIN JF., ARMAND JP., TAPHOORN MJ., TOSONI A., KLETZL H., KLUGHAMMER B., LACOMBE D., GORLIA T. Randomized Phase II Trial of Erlotinib Versus Temozolomide or Carmustine in Recurrent Glioblastoma: EORTC Brain Tumor Group Study 26034. *Journal of Clinical Oncology* 2009; 27(8): 1268_1274. 68. LACOMBE D., GORLIA T., BEAN JW., STUPP R., HEGI M., VAN DEN BENT MJ. The radical and the remedial. *Public Service Review _ European Union (Oncology)* 2009; (17): 349_351. 69. BOGAERTS J., FORD R., SARGENT D., SCHWARTZ LH., RUBINSTEIN L., LACOMBE D., EISENHAUER E., VERWEIJ J., THERASSE P., for the RECIST Working Party. Individual patient data analysis to assess modifications to the RECIST criteria. *European Journal of Cancer* 2009; 45(2): 248_260. 70. CAPONIGRO F., LACOMBE D., TWELVES C., BAUER J., GOVAERTS AS., MARREAUD S., MILANO A., ANTHONY A. An EORTC phase I study of Bortezomib in combination with oxaliplatin, leucovorin and 5 _fluorouracil in patients with advanced colorectal cancer. *European Journal of Cancer* 2009; 45(1): 48_55. 71. LEJEUNE S., LIDARSSI M., MINAS V., LACOMBE D. Les assurances pour essais cliniques en Europe: une tour de Babel? *Revue Multidisciplinaire d'Oncologie et d'Hématologie* 2010; 4(7): 233_236. 72. PALLIS AG., SHEPHERD FA., LACOMBE D., GRIDELLI C. Treatment of small _cell lung cancer in elderly patients. *Cancer* 2010; 116(5): 1192 _ 1200. 73. Awada A, Lacombe D, Liberatoscioli C. Design and performance of clinical trials in head and neck cancer. *Curr Opin Oncol.* 2010 May;22(3):184_5. doi: 10.1097/CCO.0b013e3283376aa8. Review. No abstract available. 74. PALLIS AG., WEDDING U., LACOMBE D., SOUBEYRAN P., WILDIERS H. Questionnaires and instruments for a multidimensional assessment of the older cancer patients: What clinicians need to know? *European Journal of Cancer* 2010; 46(6): 1019_1025. 75. PALLIS AG., PAPAMICHAEL D., AUDISIO R., PEETERS M., FOLPRECHT G., LACOMBE D., VAN CUTSEM E. EORTC Elderly Task Force experts' opinion for the treatment of colon cancer in older patients. *Cancer Treatment Reviews* 2010; 36(1): 83_90. 76. PALLIS AG., FORTPIED C., WEDDING U., VAN NES MC., PENNINGCKX B., RING A., LACOMBE D., MONFARDINI S., SCALLIET P., WILDIERS H. EORTC Elderly Task Force Position Paper: Approach to the older cancer patient. *European Journal of Cancer* 2010; 46(9): 1502_1513. 77. PSYRRI A., LICITRA L., LACOMBE D., SCHUURING E., BUDACH W., OZSAHIN M., KNECHT R., VERMORKEN JB., LANGENDIJK JA. Strategies to promote translational research within the European Organisation for Research and Treatment of Cancer (EORTC) Head and Neck Cancer Group: a report from the Translational Research Subcommittee. *Annals of Oncology* 2010; 21(10): 1952_1960. 78. VAN DEN BENT MJ., DUBBINK HJ., MARIE Y., BRANDES AA., TAPHOORN MJ., WESSELING P., FRENAY M., TISSEN CC., LACOMBE D., IBDIAH A., VAN MARION R., KROS JM., DINJENS WN., GORLIA T., SANSON M. IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor Group. *Clinical Cancer Research* 2010; 16(5): 1597_1604. 79. VAN LAARHOVEN HW., FIEDLER W., DESAR IM., VAN ASTEN J., MARREAUD S., LACOMBE D., GOVAERTS AS., BOGAERTS J., LASCH P., TIMMER BONTJE JN., LAMBIASE A., BORDIGNON C., PUNT CJ., HEERSCHAP A., VAN HERPEN CM. Phase I clinical and magnetic resonance imaging study of the Vascular agent NGR_hTNF in patients with advanced cancers (European Organization for Research and Treatment of Cancer Study 16041). *Clinical Cancer Research* 2010; 16(4): 1315_1323. 80. PALLIS AG., GRIDELLI C., VAN MEERBEECK JP., GREILLIER L., WEDDING U., LACOMBE D., WELCH J., BELANI CP., AAPRO M. EORTC Elderly Task Force and Lung Cancer Group and International Society for Geriatric Oncology (SIOG) experts' opinion for the treatment of non _small _cell lung cancer in an elderly population. *Annals of Oncology* 2010; (4)21: 692_706. 81. BRANDES AA., STUPP R., HAU P., LACOMBE D., GORLIA T., TOSONI A., MIRIMANOFF RO., KROS JM., VAN DEN BENT J. EORTC study 26041_22041: Phase I/II study on concomitant and adjuvant temozolomide (TMZ) and radiotherapy (RT) with PTK787/ZK222584 (PTK/ZK) in newly diagnosed glioblastoma. *European Journal of Cancer* 2010; 46(2): 348_354. 82. SCHÖFFSKI P., BLAY J_Y., DE GREVE J., BRAIN E., MACHIELS J_P., SORIA J_C., SLEIJFER S., WOLTER P., RAY_COQUARD I., FONTAINE C., MUNZERT G., FRITSCH H., HANFT G., AERTS C., RAPION J., ALLGEIER A., BOGAERTS J., LACOMBE D. Multicentric parallel phase II trial of the polo _like kinase 1inhibitor BI 2536 in patients with advanced head and neck cancer, breast cancer, ovarian cancer, soft tissue sarcoma and melanoma. The first protocol of the European Organization for Research and Treatment of Cancer (EORTC) Network Of Core Institutes (NOCI). *European Journal of Cancer* 2010; 46(12): 2206_2215. 83. MEUNIER F., LACOMBE D., BEAN J. Collaborate and conquer. *Public Service Review _ European Science & Technology* 2011; (11): 348 _ 349. 84. WELLER M., GORLIA T., CAIRNCROSS JG., VAN DEN BENT MJ., MASON W., BELANGER K., BRANDES AA., BOGDAN U., MACDONALD DR., FORSYTH P., ROSSETTI AO., LACOMBE D., MIRIMANOFF RO., VECHT CJ., STUPP R. Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide trial for glioblastoma. *Neurology* 2011; 77(12): 1156_1164. 85. STUPP R., TOSONI A., BROMBERG JE., HAU P., CAMPONE M., GIJTENBEEK J., FRENAY M., BREIMER L., WIESINGER H., ALLGEIER A., VAN DEN BENT MJ., BOGDAN U., VAN DER GRAAF W., YUN HJ., GORLIA T., LACOMBE D., BRANDES AA. Sagopilone (ZK_EPO, ZK 219477) for recurrent glioblastoma. A phase II multicenter trial by the European Organisation for Research and Treatment of Cancer (EORTC) Brain Tumor Group. *Annals of Oncology* 2011; 22(9): 2144_2149. 86. HALL J., DAIDONE MG., PETERS GJ., HARBECK N., LACOMBE D., SLEIJFER S. Integrating collection of biospecimens in clinical trials: The approach of the European Organisation for Research and Treatment of Cancer (EORTC). *Biopreservation and biobanking* 2011; 9(2): 181_186. 87. Rampling R, Sanson M, Goria T, Lacombe D, Lai C, Gharib M, Taal W, Stoffregen C, Decker R, van den Bent MJ. A phase I study of LY317615 (enzastaurin) and temozolomide in patients with gliomas (EORTC trial 26054). *Neuro Oncol.* 2012 Mar;14(3):344_50. doi: 10.1093/neuonc/nor221. Epub 2012 Jan 29. 88. LACOMBE D., NEGROUK A., BEAN J. International investigator _driven clinical trials: challenges and opportunities for US _Europe cooperation through the US cooperative group networks. *Clinical Investigation* 2011; 1(4): 493_500. 89. MEUNIER F., BEAN J., LACOMBE D.

Funding treatments, finding trials. Public Service Review _ European Union (Oncology) 2011; (21): 210 – 211. 90. LACOMBE D., BEAN J., BOGAERTS J., BOTTOMLEY A., COLLETTE L., GILOTAY C., MARINUS A., MARREAU S., RUYSKART P., SYLVESTER R., MEUNIER F. 50 years of the EORTC and the central role of the EORTC Headquarters. European Journal of Cancer 2012; 1 (Suppl. 10): 3_12. 91. WICK W., VAN DEN BENT M., VECHT C., BRANDES A., LACOMBE D., GORLIA T., ALLGEIER A., BAUMERT B., SOFFIETTI R., SANSON M., KARIM ABMF., MIRMANOFF RO., TAPHOORN M., KROS M., HEGI M., STUPP R., on behalf of the EORTC BRAIN TUMOR GROUP. EORTC topics in neurooncology: The long path from a focus on neurological complications of cancer towards molecularly defined trials and therapies in neurooncology. European Journal of Cancer 2012; 1 (Suppl. 10): 20_26. 92. WHITTAKER S., KNOBLER R., ORTIZ P., VERMEER M., KARRASCH M., HASAN B., LACOMBE D., KEMPF W., DUMMER R., BAGOT M., on behalf of the EORTC CUTANEOUS LYMPHOMA TASK FORCE (CLTF). Major achievements of the EORTC Cutaneous Lymphoma Task Force (CLTF). European Journal of Cancer 2012; 1 (Suppl. 10): 46_50. 93. HALL J., BEAN J., BREYSSSENS H., ENGELEN K., LACOMBE D., MEUNIER F. Accès aux échantillons biologiques: la clé pour les recherches cliniques en oncologie. Healthcare Executive 2012; 64: 47_50. 94. HALL J., BEAN J., BREYSSSENS H., ENGELEN K., LACOMBE D., MEUNIER F. Accès aux échantillons biologiques: la clé pour les recherches cliniques en oncologie. Revue multidisciplinaire d'Oncologie et d'Hématologie 2012; 6(1): 8_13. 95. BEAN J., LACOMBE D., MEUNIER F. Fifty Years of Progress Against Cancer _ The European Organisation for Research and Treatment of Cancer Celebrates its Achievements. European Oncology & Haematology 2012; 8(1): 10_13. 96. FAIRCHILD A., BAR_DEROMA R., COLLETTE L., HAUTERMANS K., HURKMANS C., LACOMBE D., MAINGON P., POORTMANS P., TOMSEJ M., WEBER DC., GREGOIRE V. Development of clinical trial protocols involving advanced radiation therapy techniques: The European Organisation for Research and Treatment of Cancer Radiation Oncology Group approach. European Journal of Cancer 2012; 48(7): 1048_1054. 97. FRANCESCHI E., STUPP R., VAN DEN BENT MJ., VAN HERPEN C., LAIGLE DONADEY F., GORLIA T., HEGI M., LHERMITTE B., STRAUSS LC., ALLGEIER A., LACOMBE D., BRANDES AA. EORTC 26083 phase I/II trial of dasatinib in combination with CCNU in patients with recurrent glioblastoma. Neuro_Oncology 2012; 14(12): 1503_1510. 98. LALAMI Y., SPECENIER PM., AWADA R., LACOMBE D., LIBERATOSCIOLI C., FORTPIED C., EL_HARIRY I., BOGAERTS J., LANGENDIJK JA., VERMORKEN J. EORTC 24051: Unexpected side effects of a phase I study of TPF induction chemotherapy followed by chemoradiation with lapatinib, a dual EGFR/Erbb2 inhibitor, in patients with locally advanced resectable larynx and hypopharynx squamous cell carcinoma. Radiotherapy and Oncology 2012; 105(2): 238_240. 99. BLAY J_Y., LACOMBE D., MEUNIER F., STUPP R. Personalised medicine in oncology: Questions for the next 20 years. Lancet Oncology 2012; 13(5): 448_449. 100. PLOQUIN A., OLMOS D., LACOMBE D., A'HERN R., DUHAMEL A., TWELVES C., MARSONI S., MORALES_BARRERA R., SORIA J.C., VERWEIJ J., VOEST E.E., SCHÖFFSKI P., SCHELLENS J.H., KRAMAR A., KRISTELEIT RS., ARKENAU HT., KAYE SB., PENEL N. Prediction of early death among patients enrolled in phase I trials: development and validation of a new model based on platelet count and albumin. British Journal of Cancer 2012; 107(7): 1025_1030. 101. BADY P., SCIUSCIO D., DISERENS A_C., BLOCH J., VAN DEN BENT M J., MAROSI CH., DIETRICH P_Y., WELLER M., MARIANI L., HEPPNER FL., MCDONALD DR., LACOMBE D., STUPP R., DELORENZI M., HEGI ME. MGMT methylation analysis of glioblastoma on the Infinium methylation BeadChip identifies two distinct CpG regions associated with gene silencing and outcome, yielding a prediction model for comparisons across datasets, tumor grades, and CIMP_status. Acta Neuropathologica 2012; 124(4): 547_560. 102. FAIRCHILD A., AIRD E., FENTON P., GREGOIRE V., GULYBAN A., LACOMBE D., MATZINGER O., POORTMANS P., RUYSKART P., WEBER D., HURKMANS C. EORTC Radiation Oncology Group quality assurance platform: establishment of a digital central review facility. Radiotherapy & Oncology 2012; 103(3): 279_286. 103. RAMLING R., SANSON M., GORLIA T., LACOMBE D., LAI C., GHARIB L., TAAL W., STOFFREGEN C., DECKER R., VAN DEN BENT M. A phase I study of LY317615 (enzastaurin) and temozolomide in patients with gliomas (EORTC trial 26054). Neuro_Oncology 2012; 14(3): 344_350. 104. LACOMBE D. Glufosfamide: can we improve the process of anticancer agent development? Expert Opinion Investigational Drugs 2012; 21(5): 749_754. 105. LACOMBE D., BEAN J., HALL J., MEUNIER F. Molecular Momentum. How a multidisciplinary approach and pragmatic trials can benefit patients. Public Service Review _ European Science & Technology (Oncology) 2012; (14): 176_177. 106. GORLIA T., STUPP R., BRANDES AA., RAMPLING RR., FUMOLEAU P., DITTRICH C., CAMPONE MM., TWELVES CC., RAYMOND E., HEGI ME., LACOMBE D., VAN DEN BENT MJ. New prognostic factors and calculators for outcome prediction in patients with recurrent glioblastoma: A pooled analysis of EORTC Brain Tumour Group phase I and II clinical trials. European Journal of Cancer 2012; 48(8): 1176_1184. 107. LACOMBE D., BUROCK S., BEAN J. The Evolving Clinical Trials Landscape: perspective of the EORTC. 20/20 Pharma 2013. 108. VAN DEN BENT MJ., BRANDES AA., TAPHOORN MJ., KROS JM., KOUWENHOVEN MC., DELATTRE JY., BERNSEN HJ., FRENAY M., TIJSSEN CC., GRISOLD W., SIPOUS L., ENTING RH., FRENCH PJ., DINJENS WN., VECHT CJ., ALLGEIER A., LACOMBE D., GORLIA T., HOANG_XUAN K. Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long_term follow_up of EORTC brain tumor group study 26951. Journal of Clinical Oncology 2013; 31(3): 344_350. 109. LACOMBE D., BEAN J., RUYSKART P. and MEUNIER F. Cracking cancer's complexities. Science Omega Review UK 2013; (1): 134_137. 110. LACOMBE D., LIU Y. The future of clinical research in oncology: where are we heading to? Chinese Clinical Oncology 2013; 2(1): 1_7. 111. Keat N, Law K, McConnell A, Seymour M, Welch J, Trimble T, Lacombe D, Negrouk A. International Rare Cancers Initiative (IRCI). Ecanermedscience. 2013 May 21;7:ed20. doi:10.3332/ecancer.2013.ed20. eCollection 2013. 112. LEJEUNE S., LACOMBE D. Towards personalized medicine in the EU: what is needed to facilitate the complex international clinical research? Personalized Medicine 2013; 10(8): 849_857. 113. BUROCK S., MEUNIER F., LACOMBE D. How can innovative forms of clinical research contribute to deliver affordable cancer care in an evolving health care environment? European Journal of Cancer 2013; 49(13): 2777_2783. 114. LACOMBE D., BUROCK S., MEUNIER F. Academia_Industry Partnerships: Are we ready for new models of partnership? The point of view of the EORTC, an academic clinical cancer research organization. European Journal of Cancer 2013; 49(1): 1_7. 115. GORLIA T., WU W., WANG M., BAUMERT BG., MEHTA M., BUCKNER JC., SHAW E., BROWN P., STUPP R., GALANIS E., LACOMBE D., VAN DEN BENT MJ. New validated prognostic models and prognostic calculators in patients with low_grade gliomas diagnosed by central pathology review: a pooled analysis of EORTC/RTOG/NCCTG phase III clinical trials. Neuro_Oncology 2013; 15(11): 1568_1579. 116. JAMAL R., GOODWIN RA., TU D., WALSH W., LACOMBE D., EISENHAEUER EA. Performance of multinomial designs in comparison with response_based designs in non_randomized phase II trials of targeted cancer agents. Annals of Oncology 2013; 24(7): 1936_1942. 117. SHASH E., NEGROUK A., MARREAU S., GOLFINOPOULOS V., LACOMBE D., MEUNIER F. International Clinical Trials Setting for Rare Cancers: Organizational and Regulatory Constraints – The EORTC perspective. Ecanermedscience 7: 321. 118. GORLIA T., DELATTRE JY., BRANDES AA., KROS JM., TAPHOORN MJ., KOUWENHOVEN MC., BERNSEN HJ., FRENAY M., TIJSSEN CC., LACOMBE D., VAN DEN BENT MJ. New clinical, pathological and molecular prognostic models and calculators in patients with locally diagnosed anaplastic oligodendroglioma or oligoastrocytoma. A prognostic factor analysis of European Organisation for Research and Treatment of Cancer Brain Tumour Group Study 26951. European Journal of Cancer 2013; 49(16): 3477_3485. 119. PAOLETTI X., LE TOURNEAU C., VERWEIJ J., SIU L., SEYMOUR L., POSTEL_VINAY S., COLLETTE L., RIZZO E., IVY P., OLMOS D., MASSARD CH., LACOMBE D., KAYE SB., SORIA JC. Defining dose_limiting toxicity for phase 1 trials of molecularly targeted agents: Results of a DLT_TARGETT international survey. European Journal of Cancer 2014; 50(12): 2050_2056. 120. LIU Y., LACOMBE D., STUPP R. The changing world of drug development: an academic research organization's perspective on the "seven wonders" of the future world of anti_cancer drug development. Chinese Clinical Oncology 2014; 3(2): 1_7. 121. LACOMBE D., TEJPAS S., SALGADO R., CARDOSO F., GOLFINOPOULOS V., AUST D., FOLPRECHT G., ROTH A., STUPP R. European perspective for effective cancer drug development. Nature Reviews Clinical Oncology 2014; 11(8): 492_498. 122. LACOMBE D. How Europe can develop better, cheaper cancer drugs. Cancer World 2014; (60): 49_54. 123. LACOMBE D., Director of the European Organisation for Research and Treatment of Cancer, discusses the organisation's multidisciplinary work towards improving cancer clinical trials. International Innovation 2014; (140): 15_17. 124. NEGROUK A., LACOMBE D., TRIMBLE EL., SEYMOUR M. Clinical research for rare cancers: is it a reality in the global regulatory landscape? The international rare cancer initiative. Expert Opinion on Orphan Drugs 2014; 2(5): 1_8. 125. LACOMBE D., BUROCK S., BOGAERTS J., SCHÖFFSKI P., GOLFINOPOULOS V., STUPP R. The dream and reality of histology agnostic cancer clinical trials. Molecular Oncology 2014; 8(6): 1057_1063. 126. Bogaerts J, Sydes MR, Keat N, McConnell A, Benson A, Ho A, Roth A, Fortpied C, Eng C, Peckitt C, Coens C, Pettaway C, Arnold D, Hall E, Marshall E, Sclafani F, Hatcher H, Earl H, Ray_Coquard I, Paul J, Blay JY, Whelan J, Panageas K, Wheatley G, Harrington K, Licitra L, Billingham L, Hensley M, McCabe M, Patel PM, Carvajal R, Wilson R, Glynn Jones R, McWilliams R, Leyvraz S, Rao S, Nicholson S, Filiaci V, Negrouk A, Lacombe D, Dupont E, Pauporté I, Welch JJ, Law K, Trimble T, Seymour M. Clinical trial designs for rare diseases: studies developed and discussed by the International Rare Cancers Initiative. Eur J Cancer. 2015 Feb;51(3):271_81. doi: 10.1016/j.ejca.2014.10.027. Epub 2014 Dec 24. Review. 127. POSTEL_VINAY S., COLLETTE

L., PAOLETTI X., RIZZO E., MASSARD C., OLMOS D., FOWST C., LEVY B., MANCINI P., LACOMBE D., IVY P., SEYMOUR L., LE TOURNEAU C., SIU LL., KAYE SB., VERWEI J., SORIA JC. Towards new methods for the determination of dose limiting toxicities and the assessment of the recommended dose for further studies of molecularly targeted agents _ Dose_ Limiting Toxicity and Toxicity Assessment Recommendation Group for Early Trials of Targeted therapies, an European Organisation for Research and Treatment of Cancer-led study. *European Journal of Cancer* 2014; 50(12):2040–2049. 128. Kros JM, Huizer K, Hernandez Jain A, Marucci G, Michotte A, Pollo B, Rushing E, Ribalta T, French PJ, Jaminé D, Bekka N, Lacombe D, Van Den Bent MJ, Gorlia T. An evidence-based diagnostic algorithm for glioma: analysis of the results of pathology panel review and molecular parameters of EORTC trials 26951 and 26882. *J Clin Oncol* 2015; 33 (17):1943–1950. 129. Bean J, Varin E, Szepessy E, Lacombe D. NGS and EORTC's SPECTRA hope for cancer patients. *HHE* 2015;3_5. 130. Lacombe D, Tabernero J, Voest E. Translating basic research to the patient's bedside. *ESMO Website*, 2015. 131. Lawler M, Siu LL, Rehm H, Alterovitz G, Burn J, Calvo F, Lacombe D, Tean T, North KN, Sawyers CL. All The World's a Stage: Facilitating Discovery Science and Improved Cancer Care through The Global Alliance for Genomics and Health. *Cancer Discov* 2015; 5 (11):1133–1136. 132. Menis J, Besse B, Lacombe D. Methodology of clinical trials in lung cancer. *Chin Clin Oncol* 2015 (44):1–10. 133. Baumert BG, Hegi ME, van den Bent MJ, von Deimling A, Gorlia T, Hoang_Xuan K, Brandes AA, Kantor G, Taphoorn MJB, Hassel MB, Hartmann C, Ryan G, Capper D, Kros JM, Kurscheid S, Wick W, Enting R, Reni M, Thiessen B, Dhermain F, Bromberg JE, Feuvret L, Reijneveld JC, Chinot O, Gijtenbeek JMM, Rossiter JP, Dif N, Balana C, Bravo_Marques J, Clement PM, Marosi C, Tzuk_Shina T, Nordal RA, Rees J, Lacombe D, Mason WP, Stupp R. Temozolomide chemotherapy versus radiotherapy in high_risk low_grade glioma (EORTC 22033_26033): a randomised, open_label, phase 3 intergroup study. *Lancet Oncol*. 2016 Nov;17(11):1521–1532. doi: 10.1016/S1470_2045(16)30313_8. Epub 2016 Sep 27. 134. Lacombe D. Quietly orchestrating the clinical research revolution. *Cancerworld* 2015; 68:4–10. 135. Lacombe D. Framing the frameworks. *Pan European Networks: Science & Technology* 2015; 17:220–223. 136. S. Marreaud, D. Lacombe, V. Gollfinopoulos. *ESMO Handbook Cancer Diagnosis and Treatment Evaluation. Treatment Evaluation of Activity: From Global to Personalised*. 2015, 63–66. 137. Evrard S, Audisio R, Poston G, Caballero C, Kataoka K, Fontein D, Collette L, Nakamura K, Fukuda H, Lacombe D. From A Comic Opera To Surcare An open letter to whom clinical research in surgery is of importance. *Ann Surg* 2016; 264 (4):911–912. 138. Kataoka K, Nakamura K, Caballero C, Evrard S, Negrouk A, Shiozawa M, Collette L, Fukuda H, Lacombe D. Collaboration between EORTC and JCOG how to accelerate global clinical research partnership. *Jpn J Clin Oncol*. 2017 Feb 20;47(2):164–169. doi: 10.1093/jjco/hyw159. 139. Hojgaard L, Löwenberg B, Selby P, Lawler M, Banks I, Law K, Albrecht T, Armand JP, Barbacid M, Barzack M, Bergh J, Cameron D, Conte P, de Braud F, de Gramont A, De Lorenzo F, Diehl V, Diler S, Erdem S, Geissler J, Gore_Booth J, Henning G, Horgan D, Jassem J, Johnson P, Kaasa S, Kapitein P, Karjalainen S, Kelly J, Kienesberger A, La Vecchia C, Lacombe D, Lindahl T, Luzzatto L, Malby R, Mastris K, Meunier F, Murphy M, Naredi P, Nurse P, Oliver K, Pearce J, Pelouchov J, Piccart M, Pinedo B, Spurrier_Bernard G, Sullivan R, Tabernero J, Van de Velde C, van Herk B, Vedsted P, Waldmann A, Weller D, Wilking N, Wilson R, Yared W, Zielinski C, Zur Hausen H, Le Chevalier T, Johnston P. The European Cancer Patient's Bill of Rights, update and implementation 2016. *ESMO Open*. 2017 Jan 6;1(6):e000127. doi: 10.1136/esmoopen_2016_000127. eCollection 2016. Review. 140. Tanis E, Caballero C, Collette L, Verleye L, den Dulk M, Lacombe D, Schuhmacher C, Werutsky G. The EORTC Strategy for Quality Assurance in Surgical Clinical Research: Assessment of the past and moving towards the future. *Eur J Surg Oncol* 42 (8): 1115–1122, 2016. doi: 10.1016/j.ejso.2016.04.052. Epub 2016 Apr 27. 141. Mark Trusheim, Allison Ackerman Shrier, Zoran Antonijevic, Robert A. Beckman, Robert Campbell, Cong Chen, Keith Flaherty, John Loewy, Denis Lacombe, Subha Madhava, Joseph O'Connell, Harry Selker, Laura Esserman. PIPELINES: Creating comparable clinical knowledge efficiently by linking trial platforms. *Clinical Pharmacology and Therapeutics* 100(6): 713–729, 2016. doi: 10.1002/cpt.514. Epub 2016 Oct 19 142. Trusheim M, Shrier Ackerman A, Antonijevic Z, Beckman B, Campbell R, Chen C, Flaherty K, Loewy J, Lacombe D, Madhava S, O'connel J, Selker H, Esserman L. PIPELINES: Creating comparable clinical knowledge efficiently by linking trial platforms. *Clin Pharmacol Ther* 2016; 100 (6):713–729. 143. Lawler M, Banks I, Law K, Albrecht T, Armand JP, Barbacid M, Barzack M, Bergh J, Cameron D, Conte P, de Braud F, de Gramont A, De Lorenzo F, Diehl V, Diler S, Erdem S, Geissler J, Gore_Booth J, Henning G, Hojgaard L, Horgan D, Jassem J, Johnson P, Kaasa S, Kapitein P, Karjalainen S, Kelly J, Kienesberger A, La Vecchia C, Lacombe D, Lindahl T, Lowenberg B, Luzzatto L, Malby R, Mastris K, Meunier F, Murphy M, Naredi P, Nurse P, Oliver K, Pearce J, Pelouchov J, Piccart M, Pinedo B, Spurrier_Bernard G, Sullivan R, Tabernero J, Van de Velde C, van Herk B, Vedsted P, Waldmann A, Weller D, Wilking N, Wilson R, Yared W, Zielinski C, Zur Hausen H, Le Chevalier T, Johnston P, Selby PM. The European Cancer Patient's Bill of Rights, update and implementation 2016. *ESMO Open*, <http://esmoopen.bmj.com/content/1/6/e000127> 144. O'Connor JPB, Aboagye EO, Adams JE, Aerts HJWL, Barrington SF, Beer AJ, Boellaard R, Bohndiek SE, Brown G, Brady M, Buckley DL, Chenevert TL, Clarke LP, Collette S, Cook GJ, deSouza NM, Dickson JC, Dive C, Evelhoch JL, Faivre_Finn C, Gallagher FA, Gilbert FJ, Gillies RJ, Goh V, Griffiths JR, Groves AM, Halligan S, Harris AL, Hawkes DJ, Hoekstra OS, Huang EF, Hutton BF, Jayson GC, Jones A, Koh DM, Lacombe D, Lambin P, Lassau N, Leach MO, Lee TY, Leen EL, Lewis JS, Liu Y, Lythgoe MF, Manoharan P, Maxwell RJ, Miles KA, Morgan B, Morris S, Ng T, Padhani AR, Parker GJM, Partridge M, Pathak AP, Peet AC, Punwani S, Reynolds AR, Robinson SP, Shankar LK, Sharma RA, Soloviev D, Stroobants S, Sullivan C, Taylor SA, Tofts PS, Tozer GM, van Herk M, Walker_Samuel S, Wason J, Williams KJ, Workman P, Yankeelov TE, Brindle KM, McShane LM, Jackson A, Waterton JC. Imaging biomarker roadmap for cancer studies. *Nat Rev Clin Oncol* 2017; 14:169–186. <http://doi.org/10.1038/nrclinonc.2016.162>. 145. Negrouk A, Lacombe D, Cardoso F, Morin F, Carrasco E, Maurel J, Maibach R, Aranda E, Marais R, Stahel RA. Safeguarding the future of independent, academic clinical cancer research in Europe for the benefit of patients. *ESMO Open*. 2017 Aug 3;2(3):e000187. doi: 10.1136/esmoopen_2017_000187. eCollection 2017. 146. Aapro M, Astier A, Audisio R, Banks I, Bedossa P, Brain E, Cameron D, Casali P, Chiti A, De Mattos_Arruda L, Kelly D, Lacombe D, Nilsson PJ, Piccart M, Poortmans P, Riklund K, Saeter G, Schrappe M, Soffietti R, Travado L, van Poppel H, Wait S, Naredi P. Identifying critical steps towards improved access to innovation in cancer care: a European CanCer Organisation position paper. *Eur J Cancer*. 2017 Sep;82:193–202. doi: 10.1016/j.ejca.2017.04.014. Epub 2017 Jul 7. 147. Salgado R, Moore H, Martens JWM, Lively T, Malik S, McDermott U, Michiels S, Moscow JA, Tejpar S, McKee T, Lacombe D; IBCD_Faculty. Societal challenges of precision medicine: Bringing order to chaos. *Eur J Cancer*. 2017 Oct;84:325–334. doi: 10.1016/j.ejca.2017.07.028. Epub 2017 Sep 4. 148. Kempf E, Bogaerts J, Lacombe D, Liu L. 'Mind the gap' between the development of therapeutic innovations and the clinical practice in oncology: A proposal of the European Organisation for Research and Treatment of Cancer (EORTC) to optimise cancer clinical research. *Eur J Cancer*. 2017 Nov;86:143–149. doi: 10.1016/j.ejca.2017.08.028. Epub 2017 Oct 4. 149. Tryfonidis K, Hartmann K, Morfouace M, Lacombe D. From bench to clinical trials the EORTC experience in biology_based clinical cancer research. *J Egypt Natl Canc Inst*. 2017 Dec;29(4):171–176. doi: 10.1016/j.jnci.2017.09.001. Epub 2017 Nov 6. Review. 150. Salgado R, Moore H, Martens JWM, Lively T, Malik S, McDermott U, Michiels S, Moscow JA, Tejpar S, McKee T, Lacombe D; IBCD_Faculty. Steps forward for cancer precision medicine. *Nat Rev Drug Discov*. 2018 Jan;17(1):1–2. doi: 10.1038/nrd.2017.218. Epub 2017 Nov 24. 151. Broes S, Lacombe D, Verlinden M, Huys I. Toward a Tiered Model to Share Clinical Trial Data and Samples in Precision Oncology. *Front Med (Lausanne)*. 2018 Jan 29;5:6. doi: 10.3389/fmed.2018.00006. eCollection 2018. 152. Langendijk JA, Orecchia R, Haustermans K, Zips D, Balosso J, Lacombe D, Lievens Y, Weber DC, Grau C, Troost EGC. Prospective data registration and clinical trials for particle therapy in Europe. *Radiother Oncol*. 2018 Jul;128(1):9–13. doi: 10.1016/j.radonc.2018.06.001. Epub 2018 Jul 7. Review. 153. Pilette C, Brightling C, Lacombe D, Brusselle G. Urgent need for pragmatic trial platforms in severe asthma. *Lancet Respir Med*. 2018 Aug;6(8):581–583. doi: 10.1016/S2213_2600(18)30291_1. 154. Negrouk A, Lacombe D. Does GDPR harm or benefit research participants? An EORTC point of view. *Lancet Oncol*. 2018 Oct;19(10):1278–1280. doi: 10.1016/S1470_2045(18)30620_X. Epub 2018 Oct 1. 155. Kataoka K, Kaider_Person O, Kasper B, Starlinger P, Caballero C, Menis J, Hendriks LE, Terada M, Collette L, Nakamura K, Lacombe D, Fukuda H. Responding to the challenges of international collaborations between the east and the west _ report of the first JCOG_EORTC symposium and a perspective from young JCOG and EORTC investigators. *Jpn J Clin Oncol*. 2019 Jan 1;49(1):96–99. doi: 10.1093/jjco/hyy155. 156. Lacombe D, Bogaerts J, Tombal B, Maignen F, Osipenko L, Sullivan R, Gollfinopoulos V. Late translational research: putting forward a new model for developing new anti_cancer treatments that addresses the needs of patients and society. *Mol Oncol*. 2019 Mar;13(3):558–566. doi: 10.1002/1878_0261.12431. Epub 2019 Jan 19. Review. 157. Lacombe D, O'Morain C, Casadei B, Hill K, Mateus E, Lories R, Brusselle G. Moving forward from drug_centred to patient_centred research: A white paper initiated by EORTC and developed together with the BioMed Alliance members. *Eur Respir J*. 2019 Feb 21;53(2). pii: 1801870. doi: 10.1183/13993003.01870_2018. Print 2019 Feb. 158. Lacombe D, Quaglio G, Lejeune S, Saesen R, Rübig P. Establishing treatment optimisation as part of personalised medicine development. *Eur J Cancer*. 2019

May;113:96_97. doi: 10.1016/j.ejca.2019.03.014. Epub 2019 Apr 15. 159. Salgado R, Solit DB, Rimm DL, Bogaerts J, Canetta R, Lively T, Lyerly K, Span PN, Bateman House A, Makady A, Bergmann L, Nagai S, Smith C, Robson M, Savage M, Voest E, Sweeney C, Lambin P, Thomas M, Harris L, Lacombe D, Massard C; IBCD_Faculty. Addressing the dichotomy between individual and societal approaches to personalised medicine in oncology. *Eur J Cancer*. 2019 Jun;114:128_136. doi: 10.1016/j.ejca.2019.03.025. Epub 2019 May 3. 160. Lacombe, D., Golfinopoulos, V., Negrouk, A., & Tombal, B. (2020). Clinical research in Europe: Who do we do all that for? *Journal of Cancer Policy*, 23(October 2019), 100217. <https://doi.org/10.1016/j.jcpo.2020.100217> 161. Gillian Thomas, Elizabeth Eisenhauer, Robert G. Bristow, Cai Grau, Coen Hurkmans, Piet Ost, Matthias Guckenberger, Eric Deutsch, Denis Lacombe, Damien C. Weber, Writing committee on behalf of the European Organisation for Research and Treatment of Cancer (EORTC), The European Organisation for Research and Treatment of Cancer, State of Science in radiation oncology and priorities for clinical trials meeting report. *European Journal of Cancer* 131 (2020) 76e88; <https://doi.org/10.1016/j.ejca.2020.02.05> 162. Berns A, Ringborg U, Eggermont A, Baumann M, Calvo F, Eggert A, Espina C, Hanahan D, Lacombe D, de Lorenzo F, Oberst S, Philip T, Schüz J, Tabernero J, Celis JE. Towards a Cancer Mission in Horizon Europe. *Mol Oncol*. 2019 Nov;13(11):2301_2304. https://doi.org/10.1002/1878_0261.12585. 163. Berns A, Ringborg U, Celis JE, Heitor M, Aaronson NK, Abou. Zeid N, Adami HO, Apostolidis K, Baumann M, Bardelli A, Bernards R, Brandberg Y, Caldas C, Calvo F, Dive C, Eggert A, Eggermont A, Espina C, Falkenburg F, Foucaud J, Hanahan D, Helbig U, Jönsson B, Kalager M, Karjalainen S, Kásler M, Kearns P, Kärre K, Lacombe D, de Lorenzo F, Meunier F, Nettekoven G, Oberst S, Nagy P, Philip T, Price R, Schüz J, Solary E, Strang P, Tabernero J, Voest E. Towards a cancer mission in Horizon Europe: recommendations. *Mol Oncol*. 2020 Aug;14(8):1589_1615. https://doi.org/10.1002/1878_0261.12763. 164. 163. Ringborg U, Berns A, Celis J, Heitor M, Tabernero J, Baumann M, Henrique R, Aapro M, Basu P, Beets Tan R, Besse B, Cardoso F, Carneiro F, van den Eede G, Eggermont A, Frohling S, galbraith S, Garralda E, Hanahan D, Hofmarcher T, Jonsson B, Kallioniemi O, Kasler M, Kondorosi E, Korbel J, Lacombe D, Machado JC, Martin Moreno JM, Meunier F, Nagy P, Nucifero P, Oberst S, Oliveira , Papatriantafyllou M, Ricciardi W, Roediger A, Ryll B, Schilsky R, Scocca G, Seruca R, Soares M, Steindorf K, Valentini V, Voest E, Weiderpass E, Wilking N, Wren A, Zitvogel L. The Porto European Cancer Research Summit 2021. *Mol Oncol* 2021. https://doi.org/10.1002/1878_0261.13078

Projects

Memberships

- Full Member of the General Assembly of the Cancer Drug Development Forum (CDDF) • Member of the European Forum for Good Clinical Practice (EFGCP) • Member of the General Assembly of the European Cancer Organisation (E.C.O.) and Co_Chair of the Health Systems and Treatment Optimisation Network • Member of the General Assembly of BioMed Alliance • Member of Commission Expert Group on Cancer Control (2014_on going) • Corresponding Member of the American Association for Cancer Research (AACR) • Member of the European Society of Medical Oncology (ESO) • Member of the American Society of Clinical Oncology (ASCO) • Member of the Belgium College of Pharmaceutical Medicine (till 2011) • Lecturer for the 3rd cycle of pharmacology applied to pharmaceutical industry, (Pharmed) Free University of Brussels 2003_on going • Member of the Scientific Advisory Group Oncology (SAG) of Committee for Medicinal Products for Human Use (CHMP) at EMEA/EMA (10/2006). • Member « Comité d'orientation stratégique de la direction scientifique.Comite de revue des protocoles (COS_CRP) UNICANCER France (05/2008_2015) • Président Conseil Scientifique du Centre G_F Leclerc (2009_2018) • Member of the CIR2C (French INCa) (2014_2017) • Member of the General Assembly of WIN (2014_2016) • Member of Commission Expert Group on Cancer Control (2014_on going) • Member of Vlerick Business School, Advisory Board • Fellow of the European Academy of Cancer Sciences (2015)

Other Relevant Information